Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
Leukemia is not just one disease

Leukemia is not just one disease

People who have a parent, sibling, or child with blood cancer have higher risk of disease

People who have a parent, sibling, or child with blood cancer have higher risk of disease

New leukemia treatment developed from common wild flower

New leukemia treatment developed from common wild flower

Combination treatment effective as front-line therapy for select chronic lymphocytic leukemia patients

Combination treatment effective as front-line therapy for select chronic lymphocytic leukemia patients

Study identifies patterns of chronic lymphocytic leukemia growth

Study identifies patterns of chronic lymphocytic leukemia growth

Researchers identify why lymphoma patients may become resistant to specific drug

Researchers identify why lymphoma patients may become resistant to specific drug

New test could be a ‘game changer’ in the treatment of chronic lymphocytic leukemia

New test could be a ‘game changer’ in the treatment of chronic lymphocytic leukemia

EU-funded project investigates molecular mechanisms of aging in adult stem cells

EU-funded project investigates molecular mechanisms of aging in adult stem cells

New approach identifies epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment

New approach identifies epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment

New strategies may improve performance of CAR-T cell therapy in treating cancer

New strategies may improve performance of CAR-T cell therapy in treating cancer

FDA approves new combination therapy for acute myeloid leukemia

FDA approves new combination therapy for acute myeloid leukemia

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Barcelona researchers win one of the most prestigious EU grants to study CLL

Barcelona researchers win one of the most prestigious EU grants to study CLL

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

New study links stress with biological disease markers in leukemia patients

New study links stress with biological disease markers in leukemia patients